| Literature DB >> 28400924 |
Loïc Bière1, Marjorie Niro1, Hervé Pouliquen1, Jean-Baptiste Gourraud1, Fabrice Prunier1, Alain Furber1, Vincent Probst1.
Abstract
AIM: To assess the arrhythmic determinants and prognosis of patients presenting with myocardial infarction and non-obstructive coronary arteries (MINOCA) with normal ejection fraction (EF).Entities:
Keywords: Cardiac magnetic resonance; Late gadolinium enhancement; Myocardial infarction; Myocardial infarction and non-obstructive coronary arteries; Myocarditis; Ventricular tachycardia
Year: 2017 PMID: 28400924 PMCID: PMC5368677 DOI: 10.4330/wjc.v9.i3.268
Source DB: PubMed Journal: World J Cardiol
Figure 1Flow chart of the study population. CMR: Cardiac magnetic resonance; LGE: Late gadolinium enhancement.
Figure 2Pattern of late gadolinium enhancement. A: Incidence of late gadolinium enhancement (LGE) within each segment (percentage) of all patients, including those with and without LGE. In myocarditis cases, LGE was predominantly on the lateral wall. In myocardial infarction, no specific pattern of LGE could be identified; B: Representative short-axis slice images showing LGE location; C: Superimposed segmental models showing location and spatial extent of LGE (outlined).
Patient characteristics
| Age, yr | 48.5 ± 16.1 | 52.4 ± 14.2 | 40.5 ± 13.5 | 53.4 ± 16.9 | < 0.001 |
| Risk factors, | |||||
| Male gender | 87 (66.4) | 22 (64.7) | 39 (83.0) | 26 (52.0) | 0.005 |
| Hypertension | 39 (29.8) | 13 (38.2) | 8 (17.0) | 18 (36.0) | 0.06 |
| Diabetes | 11 (8.4) | 4 (11.8) | 2 (4.3) | 5 (10.0) | 0.42 |
| Dyslipidemia | 38 (29.0) | 9 (26.5) | 10 (21.3) | 19 (38.0) | 0.18 |
| Current smoker | 45 (34.4) | 14 (41.4) | 12 (25.5) | 19 (38.0) | 0.27 |
| Family history of premature CHD | 25 (19.1) | 11 (34.2) | 5 (10.6) | 9 (18.0) | 0.05 |
| Time from symptom onset to admission, h | 9 [2; 24] | 3.5 [2; 13.5] | 13 [4; 48] | 9.5 [2; 24] | 0.01 |
| Hospitalization duration, d | 6 [4; 7] | 5.5 [4; 7] | 6 [5; 7] | 5 [4; 7] | 0.42 |
| ECG monitoring duration, d | 5 [4; 6] | 5 [4; 6] | 5 [4; 7] | 4 [3; 6] | 0.12 |
| Primary ECG abnormality, | 91 (69.5) | 26 (76.5) | 34 (72.3) | 31 (62.0) | 0.32 |
| ST-segment elevation | 46 (35.1) | 9 (26.5) | 22 (46.8) | 15 (30.0) | 0.10 |
| ST-segment depression | 8 (6.1) | 2 (5.9) | 4 (8.5) | 2 (4.0) | 0.65 |
| T-wave inversion | 31 (23.7) | 11 (32.4) | 8 (17.0) | 12 (24.0) | 0.27 |
| Q wave | 2 (1.5) | 2 (5.9) | 0 | 0 | 0.06 |
| Atrioventricular block | 1 (0.8) | 0 | 0 | 1 (2.0) | 0.28 |
| Laboratory measurements | |||||
| Peak troponin, μg/L | 2.1 ± 5 | 3.6 ± 6.1 | 2.9 ± 6.3 | 0.5 ± 0.6 | 0.013 |
| Leucocytes on admission, G/L | 9.3 ± 3.6 | 9.3 ± 3.9 | 9.2 ± 3.5 | 9.2 ± 3.4 | 0.99 |
| CRP on admission, mg/L | 28.2 ± 41.1 | 8.8 ± 18.9 | 39.5 ± 38.4 | 31.0 ± 50.4 | 0.004 |
| Coronary atheroma, | 45 (34.6) | 15 (45.5) | 14 (29.8) | 16 (32.0) | 0.31 |
| β-blocker use, | |||||
| During hospitalization | 91 (69.5) | 27 (79.4) | 31 (66.0) | 33 (66.0) | 0.34 |
| At 1 yr | 16 (12.2) | 10 (29.4) | 1 (2.1) | 5 (10.0) | 0.05 |
| ACEI use, | |||||
| During hospitalization | 56 (43.1) | 16 (48.5) | 16 (34.0) | 24 (48.0) | 0.29 |
| At 1 yr | 17 (13.0) | 10 (29.4) | 1 (2.1) | 6 (12.0) | 0.042 |
P significant between MI and myocarditis groups;
P significant between MI and “no LGE” groups;
P significant between myocarditis and “no LGE” groups. MI: Myocardial infarction; LGE: Late gadolinium enhancement; ACEI: Angiotensin converting enzyme inhibitor; CHD: Coronary heart disease; CRP: C-reactive protein.
Cardiac magnetic resonance parameters
| LVEF (%) | 58.6 ± 8.2 | 57.1 ± 7.8 | 57.9 ± 8.6 | 60.2 ± 7.8 | 0.18 |
| LVEDV (mL) | 154.7 ± 37.7 | 158.8 ± 41 | 159.6 ± 28.6 | 147.3 ± 42.1 | 0.21 |
| LVESV (mL) | 64.5 ± 22.1 | 69.5 ± 25.5 | 67.1 ± 16.9 | 58.6 ± 22.9 | 0.048 |
| LV wall thickening abnormality, | 62 (47.3) | 30 (88.2) | 22 (46.8) | 10 (20.0) | < 0.001 |
| Hypokinetic extent, segments | 1.1 ± 1.5 | 2 ± 1.6 | 1.2 ± 1.6 | 0.4 ± 1.1 | < 0.001 |
| 0 segment, | 69 (52.7) | 4 (11.8) | 25 (53.2) | 40 (80.0) | |
| 1-2 segments, | 43 (32.9) | 20 (58.8) | 14 (29.8) | 9 (18.0) | |
| > 2 segments, | 19 (14.5) | 10 (29.4) | 8 (17.0) | 1 (2.0) | |
| LGE transmural extent, segments | 0.9 ± 0.8 | 3.6 ± 0.6 | 2.1 ± 0.9 | 0 | < 0.001 |
| < 50%, | 83 (73.4) | 2 (5.9) | 31 (66.0) | 0 | |
| > 50%, | 48 (36.6) | 32 (94.1) | 16 (34.0) | 0 | |
| LGE transversal extent, segments | 1.9 ± 2.2 | 1.9 ± 1.3 | 3.5 ± 2.4 | 0 | < 0.001 |
| 0 segment, | 50 (38.2) | 0 | 0 | 50 (100.0) | |
| 1-2 segments, | 46 (35.1) | 26 (76.5) | 20 (42.6) | 0 | |
| > 2 segments, | 35 (26.7) | 8 (23.5) | 27 (57.4) | 0 | |
| LGE/CINE concordance, | 49 (37.4) | 30 (88.2) | 19 (41.3) | 0 | < 0.001 |
| Pericardial effusion, | 20 (15.3) | 4 (11.8) | 8 (17.4) | 8 (16) | 0.8 |
P significant between MI and myocarditis groups;
P significant between MI and “no LGE” groups;
P significant between myocarditis and “no LGE” groups. MI: Myocardial infarction; LGE: Late gadolinium enhancement; LV: Left ventricle; LVEDV: Left ventricular end diastolic volume; LVESV: Left ventricular end systolic volume; LVEF: Left ventricular ejection fraction.
Acute event rates
| Ventricular event, | 18 (13.8) | 9 (26.5) | 7 (14.9) | 2 (4.0) | 0.013 |
| VT, | 17 (13.0) | 9 (26.5) | 6 (12.8) | 2 (4.0) | 0.011 |
| Prolonged VT or VF, | 8 (6.1) | 4 (11.8) | 4 (8.5) | 0 | 0.06 |
| VF, | 1 (0.8) | 0 | 1 (2.1) | 0 | 0.41 |
P significant between MI and “no LGE” groups. MI: Myocardial infarction; LGE: Late gadolinium enhancement; VF: Ventricular fibrillation; VT: Ventricular tachycardia.
Acute event characteristics
| β | |||||||||||||
| 13 | Male | 39 | STE | 0.3 | 51.7 | MI | 4 | 1 | 0 | 1 | 0 | 1 | 10 VPBs |
| 52 | Male | 45 | Normal | 0.4 | 57.7 | MI | 3 | 0 | 0 | 1 | 0 | 1 | 10 VPBs |
| 53 | Female | 30 | STE | 17.3 | 45.5 | MI | 4 | 1 | 1 | 1 | 0 | 0 | 30 VPBs |
| 63 | Male | 51 | Normal | 0.3 | 57.8 | MI | 3 | 1 | 1 | 1 | 0 | 1 | 6 VPBs |
| 64 | Male | 56 | STE | 1.6 | 61.2 | MI | 4 | 1 | 1 | 1 | 0 | 1 | 15 VPBs |
| 75 | Male | 32 | STE | 0.8 | 63.2 | MI | 4 | 1 | 0 | 1 | 0 | 0 | 7 VPBs |
| 92 | Male | 57 | STD | 0.4 | 48.1 | MI | 3 | 1 | 0 | 1 | 0 | 0 | 6 VPBs |
| 128 | Female | 55 | STD | 0.6 | 49.8 | MI | 4 | 1 | 1 | 1 | 0 | 1 | 5 VPBs |
| 97 | Male | 83 | STD | 0.2 | 46.5 | MI | 2 | 1 | 1 | 1 | 0 | 0 | 6 VPBs |
| 3 | Male | 45 | STE | 0.1 | 66.9 | Myocarditis | 3 | 1 | 0 | 1 | 0 | 2 | 9 VPBs |
| 37 | Male | 40 | STE | 4.8 | 56.1 | Myocarditis | 2 | 0 | 1 | 1 | 0 | 2 | 5 VPBs |
| 44 | Male | 25 | STE | 36.6 | 65.7 | Myocarditis | 3 | 0 | 0 | 0 | 1 | 3 | VF |
| 94 | Male | 28 | STE | 1.4 | 57.1 | Myocarditis | 2 | 1 | 0 | 1 | 0 | 0 | 4 VPBs |
| 76 | Male | 53 | STE | 1.4 | 69.6 | Myocarditis | 2 | 1 | 1 | 1 | 0 | 0 | 7 VPBs |
| 104 | Female | 42 | STE | 21.2 | 57.1 | Myocarditis | 4 | 1 | 0 | 1 | 0 | 1 | 13 VPBs |
| 131 | Female | 31 | STD | 0.6 | 51.7 | Myocarditis | 1 | 1 | 0 | 1 | 0 | 1 | 8 VPBs |
| 80 | Male | 34 | STE | 0.4 | 53.1 | No LGE | 0 | 0 | 1 | 1 | 0 | 0 | 7 VPBs |
| 125 | Male | 56 | Normal | 0.1 | 62.4 | No LGE | 0 | 1 | 1 | 1 | 0 | 4 | 3 VPBs |
LGE transmural extent: 0 = 0%, 1 = 0%-25%, 2 = 25%-50%, 3 = 50%-75%, and 4 > 75%. LGE: Late gadolinium enhancement; ECG: Electrocardiography; LVEF: Left ventricular ejection fraction; STD: ST-segment depression; STE: ST-segment elevation; VT: Ventricular tachycardia; VF: Ventricular fibrillation; VPBs: Ventricular premature beats; MI: Myocardial infarction; ACEI: Angiotensin-converting enzyme inhibitor.
Univariate and multivariate analysis for ventricular arrhythmia
| STE | 4.65 (1.61-13.40) | 0.004 | 5.72 (1.77-18.46) | 0.004 |
| STD | - | 0.06 | ||
| T-wave inversion | - | 0.99 | ||
| Troponin | 1.10 (1.02-1.20) | 0.02 | - | 0.27 |
| Hypokinetic extent | - | 0.09 | ||
| LGE transmural extent | 1.52 (1.08-2.15) | 0.017 | 1.50 (1.02-2.20) | 0.039 |
| LVEF | - | 0.31 | ||
| LVEDV | - | 0.3 | ||
| LVESV | - | 0.17 | ||
| Pericardial effusion | - | 0.24 | ||
| Coronary atheroma | - | 0.68 | ||
| CMR diagnosis | - | 0.12 | ||
| MI or myocarditis | 0.17 (0.04-0.77) | 0.022 | ||
LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVEF: Left ventricular ejection fraction; STD: ST-segment depression; STE: ST-segment elevation; MI: Myocardial infarction; CMR: Cardiac magnetic resonance.